We previously reported that CEA kinetics are a marker of progressive disease (PD) in metastatic colorectal cancer (mCRC). This study was specifically designed to confirm CEA kinetics for predicting PD and to evaluate CA19-9, cell-free DNA (cfDNA), circulating tumour DNA (ctDNA) and circulating tumour cell (CTC) kinetics.
Patients starting a chemotherapy (CT) with pre-treatment CEA > 5 ng/mL and/or CA19.9 > 30 UI/mL were prospectively included. Samples were collected from baseline to cycle 4 for CEA and CA19-9 and at baseline and the sixth week for other markers. CEA kinetics were calculated from the first to the third or fourth CT cycle.
A total of 192 mCRC patients were included. CEA kinetics based on the previously identified >0.05 threshold was significantly associated with PD (p < 0.0001). By dichotomising by the median value, cfDNA, ctDNA and CA19-9 were associated with PD, PFS and OS in multivariate analysis. A circulating scoring system (CSS) combining CEA kinetics and baseline CA19-9 and cfDNA values classified patients based on high (n = 58) and low risk (n = 113) of PD and was independently associated with PD (ORa = 4.6, p < 0.0001), PFS (HRa = 2.07, p < 0.0001) and OS (HRa = 2.55, p < 0.0001).
CEA kinetics alone or combined with baseline CA19-9 and cfDNA are clinically relevant for predicting outcomes in mCRC.
Trial registration number
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Phelip, J. M., Tougeron, D., Léonard, D., Benhaim, L., Desolneux, G., Dupré, A. et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig. Liver Dis. 51, 1357–1363 (2019).
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016).
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
Hanash, S. M., Baik, C. S. & Kallioniemi, O. Emerging molecular biomarkers−blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8, 142–150 (2011).
Corcoran, R. B. & Chabner, B. A. Application of cell-free DNA analysis to cancer treatment. N. Engl. J. Med. 379, 1754–1765 (2018).
Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71–88 (2019).
Filella, X., Molina, R., Grau, J. J., Piqué, J. M., Garcia-Valdecasas, J. C., Astudillo, E. et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann. Surg. 216, 55–59 (1992).
Hanke, B., Riedel, C., Lampert, S., Happich, K., Martus, P., Parsch, H. et al. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann. Oncol. 12, 221–226 (2001).
Duffy, M. J., van Dalen, A., Haglund, C., Hansson, L., Klapdor, R., Lamerz, R. et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur. J. Cancer 39, 718–727 (2003).
Iwanicki-Caron, I., Di Fiore, F., Roque, I., Astruc, E., Stetiu, M., Duclos, A. et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J. Clin. Oncol. 26, 3681–3686 (2008).
Petrioli, R., Licchetta, A., Roviello, G., Pascucci, A., Francini, E., Bargagli, G. et al. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab. Cancer Invest. 30, 65–71 (2012).
Michl, M., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U. et al. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). Ann. Oncol. 27, 1565–1572 (2016).
Jia, J., Zhang, P., Gou, M., Yang, F., Qian, N., Dai, G. The role of serum CEA and CA19-9 in efficacy evaluations and progression-free survival predictions for patients treated with cetuximab combined with FOLFOX4 or FOLFIRI as a first-line treatment for advanced colorectal cancer. Dis Markers 2019, 6812045 (2019).
Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y. et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213–3221 (2008).
Tol, J., Koopman, M., Miller, M. C., Tibbe, A., Cats, A., Creemers, G. J. M. et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol. 21, 1006–1012 (2010).
Spindler, K. L. G., Pallisgaard, N., Vogelius, I. & Jakobsen, A. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin. Cancer Res. 18, 1177–1185 (2012).
Spindler, K. L. G., Appelt, A. L., Pallisgaard, N., Andersen, R. F., Brandslund, I. & Jakobsen, A. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int. J. Cancer 135, 2984–2991 (2014).
Tabernero, J., Lenz, H. J., Siena, S., Sobrero, A., Falcone, A., Ychou, M. et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 16, 937–948 (2015).
El Messaoudi, S., Mouliere, F., Du Manoir, S., Bascoul-Mollevi, C., Gillet, B., Nouaille, M. et al. Circulating DNA as a strong multi-marker prognostic tool for metastatic colorectal cancer patient management care. Clin. Cancer Res. 22, 3067–3077 (2016).
Hamfjord, J., Guren, T. K., Dajani, O., Johansen, J. S., Glimelius, B., Sorbye, H. et al. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. Ann. Oncol. 30, 1088–1095 (2019).
Tie, J., Kinde, I., Wang, Y., Wong, H. L., Roebert, J., Christie, M. et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann. Oncol. 26, 1715–1722 (2015).
Garlan, F., Laurent-Puig, P., Sefrioui, D., Siauve, N., Didelot, A., Sarafan-Vasseur, N. et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL Study). Clin. Cancer Res. 23, 5416–5425 (2017).
Parikh, A. R., Mojtahed, A., Schneider, J. L., Kanter, K., Van Seventer, E. E., Fetter, I. J. et al. Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin. Cancer Res. 26, 1877–1885 (2020).
Souza, E., Silva, V., Chinen, L. T. D., Abdallah, E. A., Damascena, A., Paludo, J., Chojniak, R. et al. Early detection of poor outcome in patients with metastatic colorectal cancer: tumor kinetics evaluated by circulating tumor cells. Onco Targets Ther. 9, 7503–7513 (2016).
Ma, B., King, A. D., Leung, L., Wang, K., Poon, A., Ho, W. M. et al. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Ann. Oncol. 28, 1576–1581 (2017).
Seeberg, L. T., Brunborg, C., Waage, A., Hugenschmidt, H., Renolen, A., Stav, I. et al. Survival impact of primary tumor lymph node status and circulating tumor cells in patients with colorectal liver metastases. Ann. Surg. Oncol. 24, 2113–2121 (2017).
Aggarwal, C., Meropol, N. J., Punt, C. J., Iannotti, N., Saidman, B. H., Sabbath, K. D. et al. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann. Oncol. 24, 420–428 (2013).
Sefrioui, D., Sarafan-Vasseur, N., Beaussire, L., Baretti, M., Gangloff, A., Blanchard, F. et al. Clinical value of chip-based digital-PCR platform for the detection of circulating DNA in metastatic colorectal cancer. Dig. Liver Dis. 47, 884–890 (2015).
Sefrioui, D., Mauger, F., Leclere, L., Beaussire, L., Di Fiore, F., Deleuze, J. F. et al. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients. Clin. Chim. Acta 465, 1–4 (2016).
Iwanicki-Caron, I., Basile, P., Toure, E., Antonietti, M., Lecleire, S., Di Fiore, A. et al. Usefulness of circulating tumor cell detection in pancreatic adenocarcinoma diagnosis. Am. J. Gastroenterol. 108, 152–155 (2013).
Hansen, B. B. The prognostic analogue of the propensity score. Biometrika 95, 481–488 (2008).
Thierry, A. R., El Messaoudi, S., Mollevi, C., Raoul, J. L., Guimbaud, R., Pezet, D. et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann. Oncol. 28, 2149–2159 (2017).
Thierry, A. R., Pastor, B., Jiang, Z. Q., Katsiampoura, A. D., Parseghian, C., Loree, J. M. et al. Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer. Clin. Cancer Res. 23, 4578–4591 (2017).
Farace, F., Massard, C., Vimond, N., Drusch, F., Jacques, N., Billiot, F. et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br. J. Cancer 105, 847–853 (2011).
The authors thank the patients and their families, investigators and staff from all the participating sites. The authors also thank American Journal Expert (www.aje.com) for English language editing.
Ethics approval and consent to participate
The study was approved by the institutional review board (Northwest I), and all patients provided written informed consent (NCT01212510). The study was performed in accordance with the Declaration of Helsinki.
Consent to publish
Raw data are available from the corresponding author upon request.
The authors declare no competing interests.
This study was supported in part by the Grant “Pierre DURAND & Marie-Thérèse CHEVALIER (2013)” and the pharmaceutical industrial partners Roche, Merck and Amgen France. A grant was also provided by the Charles Nicolle Foundation and the association “des tulipes contre le cancer-Lions Club de France” for financing and acquisition of the digital PCR system used for the detection of circulating tumour DNA. The Northwest Data Center (CTD-CNO) that managed the data was supported by grants from the French National League Against Cancer (LNC) and the French National Cancer Institute (INCa).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sefrioui, D., Beaussire, L., Gillibert, A. et al. CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC). Br J Cancer (2021). https://doi.org/10.1038/s41416-021-01431-9